This post was originally published on this site CareBand’s tracking bracelet, which pairs GPS technology to track movement and activity in real time, has been granted the National Institutes of Health (NIH) Phase 1 Small Business Innovation Research (SBIR) Award to test whether it may help detect and predict agitation in patients with Alzheimer’s disease…
This post was originally published on this site Men with prostate cancer who undergo surgery have similar long-term outcomes whether they receive radiation therapy shortly after the surgery or only when signs of disease recurrence appear, suggesting that some may be spared the radiation treatment, a Phase 3 clinical trial shows. Findings from the trial…
This post was originally published on this site A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial (NCT03789240) will be conducted at the National Institutes of Health Clinical Center, in Maryland, under the leadership…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that two regimens of Keytruda (pembrolizumab) be approved in Europe for first-line treatment of metastatic or inoperable recurrent head and neck squamous cell carcinoma (HNSCC). The CHMP recommends that…
This post was originally published on this site Daiichi Sankyo has submitted an application to Japanese regulatory authorities asking that its investigational therapy trastuzumab deruxtecan (DS-8201) be approved as a treatment for people with HER2-positive metastatic breast cancer. The New Drug Application (NDA) is based on results from the multi-center, randomized, open-label DESTINY-Breast01 Phase 2…
This post was originally published on this site Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early Alzheimer’s disease, following a new analysis of Phase 3 studies supporting meaningful benefits for patients’ cognition and daily life abilities. After meeting with the U.S. Food and Drug Administration (FDA),…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Cleveland Diagnostics’ IsoPSA, a minimally invasive blood test for early detection of prostate cancer. The IsoPSA test works by identifying cancer-related structural changes in a key protein. The breakthrough device designation is awarded to…
This post was originally published on this site A newly developed imaging approach that combines laser microscopy with computational analysis may make it easier to spot ovarian cancer cells that have spread to other organs, called metastasis, a study found. The new technique was described in a paper, titled “Two-photon images reveal unique texture features…
This post was originally published on this site A Phase 2 clinical trial assessing Solasia Pharma’s lead candidate darinaparsin as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL) in Asian patients has reached its target enrollment, the company announced. The Asian multinational study (NCT02653976) has recruited 67 patients across 24 sites in Japan,…
This post was originally published on this site AstraZeneca‘s Imfinzi (durvalumab) decreases the spread of cancer to other parts of the body, explaining the enhanced survival in patients with stage 3 inoperable non-small-cell lung cancer (NSCLC), according to a new analysis of Phase 3 data. This analysis of survival data was gathered from the Phase 3…
